Q3 2017

Latest Quarterly Results
Ended March 31, 2017

$714,889

Research and development YTD

$1,449,080

Net cash used in operations YTD

Latest Financial Results

Q3 2017

Quarterly Results

Ended Mar 31, 2017

Latest 10-K

Sign Up For E-Mail Alerts

Sign Up Today

Stock Information | View Detailed Stock Info

OTCQB: PPCB Propanc Biopharma, Inc.
Change
Volume
Day Range
52 Week Range

Company Overview

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

View Corporate Presentation

IR Contact Information

Investor Relations

Consulting for Strategic Growth 1
Stan Wunderlich
733 Third Avenue
16th Floor
New York, NY 10017

Transfer Agent

Corporate Stock Transfer Inc.
3200 Cherry Creek South Drive
Suite 430
Denver, CO 80209
T: 303-282-4800
dbell@corporatestock.com
www.corporatestock.com